Boehringer Ingelheim posts strong H1 growth as diabetes drug Jardiance drives sales surge Boehringer Ingelheim reported currency‑adjusted H1 revenue of €15.8 billion, up 16% year‑on‑year, boosted by Jardiance and a …
The Berlin Herald @2020 – All Right Reserved.